title: Local and genetic determinants of vascular endothelial growth factor expression in advanced proliferative diabetic retinopathy.
abstract: OBJECTIVE
  In proliferative diabetic retinopathy (PDR) and other angiogenesis-associated diseases, increased levels of cytokines, inflammatory cells, growth factors, and angiogenic factors are present. Vascular endothelial growth factor (VEGF) appears to play a central role in mediating microvascular pathology in PDR. The purpose of the present study was to search for the association between the -634 C/G polymorphism of the VEGF gene and PDR. Moreover, it was hoped to determine whether serum and vitreous levels of VEGF are affected by genetic factors.
  
  
  METHODS
  This cross-sectional case-control study enrolled 349 unrelated Slovene subjects (Caucasians) with type 2 diabetes mellitus. The case group consisted of 206 patients with an advanced form of PDR and for whom vitrectomy was performed, and the control group had 143 patients who had no clinical signs of diabetic retinopathy but did have type 2 diabetes of more than 10 years duration. To analyze the genotype distribution we had to compare the genotype frequencies in diabetics with PDR (cases, n=206) and diabetics without diabetic retinopathy (control group, n=143). Additionally, to evaluate the effect of diabetes on the VEGF serum levels 2 groups, diabetics and non diabetics, were compared. First group were diabetics (diabetics with PDR, n=104), and second group were 29 subjects without diabetes.
  
  
  RESULTS
  The -634 C/G VEGF polymorphism was not associated with PDR. Mean serum and vitreous levels of VEGF were statistically significantly higher in PDR in comparison to the control group. Moreover, significantly higher serum and vitreous levels of VEGF were demonstrated in diabetics with the CC genotype compared to those with the other (CG + GG) genotypes.
  
  
  CONCLUSIONS
  VEGF is an important cytokine in PDR. Despite the effect of the -634 C/G VEGF polymorphism on serum and vitreous levels of VEGF in PDR, it failed to contribute to the genetic susceptibility to PDR.
authors.affiliation: Eye Clinic, University Medical Centre Ljubljana, Ljubljana, Slovenia.
authors.forename: Mojca Globocnik
authors.initials: MG
authors.lastname: Petrovic
authors.forename: Peter
authors.initials: P
authors.lastname: Korosec
authors.forename: Mitja
authors.initials: M
authors.lastname: Kosnik
authors.forename: Josko
authors.initials: J
authors.lastname: Osredkar
authors.forename: Marko
authors.initials: M
authors.lastname: Hawlina
authors.forename: Borut
authors.initials: B
authors.lastname: Peterlin
authors.forename: Daniel
authors.initials: D
authors.lastname: Petrovic
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000483:Alleles; D016022:Case-Control Studies; D003930:Diabetic Retinopathy / Q000235:genetics*; D005260:Female; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide / Q000235:genetics; D012044:Regression Analysis; D042461:Vascular Endothelial Growth Factor A / Q000097:blood / Q000235:genetics*; D014822:Vitreous Body / Q000378:metabolism
chemical_list: C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A